LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming September 12, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Biohaven Ltd. ("Biohaven†or the "Company†) (NYSE: BHVN) securities between March 24, 2023 and May 14, 2025, inclusive (the "Class Period†). IF YOU ARE AN INVESTOR WHO LOST MONEY ON BIOHAVEN LTD. (BHVN), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAU. ...

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lantheus Holdings, Inc. (“Lantheus” or “the Company”) (NASDAQ: LNTH) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lant ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nutex Health Inc. (NASDAQ: NUTX). Shareholders who purchased shares of NUTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/nutex-health-inc-loss-submission-form/?id=16 ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of LifeMD, Inc. (NASDAQ: LFMD). Shareholders who purchased shares of LFMD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/lifemd-inc-loss-submission-form/?id=166350&from= ...

NEW YORK, Sept. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). Shareholders who purchased shares of UNCY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/unicycive-therapeutics-inc-loss-submission-form/?id=166344&from=4 CLASS ...

Accessibility StatementSkip Navigation SAN DIEGO, Sept. 10, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Lantheus Holdings, Inc. (NASDAQ: LNTH) securities between February 26, 2025 and August 5, 2025, inclusive (the "Class Period"), have until November 10, 2025 to seek appointment as lead plaintiff of the Lantheus class action lawsuit. Captioned Margolis v. Lantheus Holdings, Inc., No. 25-cv- 07491 (S.D.N.Y.), the Lantheus class action lawsuit charges Lanth ...

Another shareholder lawsuit alleging dodgy accounting practices at Bitcoin treasury giant Strategy has been dropped, court documents show.  Documents filed Wednesday show the scrapped case, brought in June by shareholders Abhey Parmar and Zhenqiu Chen, had alleged breaches of fiduciary duties, unjust enrichment, abuse of control, and gross mismanagement in the company.  The dismissal comes just weeks after a different class-action lawsuit accusing the company of misleading shareholders about how new account ...

集体诉讼案件 - Rosen Law Firm提醒在2024年11月7日至2025年7月8日期间购买RxSight公司证券的投资者 关于2025年9月22日的重要首席原告截止日期 [1] - 诉讼指控被告在整个集体诉讼期间作出虚假和误导性陈述 包括未披露RxSight面临“采用挑战”和结构性问题导致销售和利用率下降 [5] - 被告被指控夸大RxSight产品需求 导致公司不太可能实现其先前发布的2025财年财务指引 [5] 律所资质与业绩 - Rosen Law Firm专注于证券集体诉讼和股东衍生诉讼 2017年因证券集体诉讼和解数量被ISS证券集体诉讼服务评为第一名 [4] - 该律所自2013年以来每年排名前四 为投资者追回数亿美元 2019年单独为投资者获得超过4.38亿美元 [4] - 创始合伙人Laurence Rosen在2020年被law360评为原告律师界的泰斗 多名律师获得Lawdragon和Super Lawyers认可 [4] 投资者参与方式 - 投资者可通过访问指定网址或联系Phillip Kim律师加入RxSight集体诉讼 无需支付任何自付费用或成本 [2][3] - 投资者若希望担任首席原告 必须在2025年9月22日前向法院提出动议 首席原告是代表其他集体成员指导诉讼的代表方 [3] - 在集体认证前投资者不被律师代表 可选择自行聘请律师或保持缺席集体成员身份 未来获得赔偿的能力不依赖于担任首席原告 [7]

诉讼背景 - 格罗斯律师事务所向Sable Offshore Corp (NYSE SOC) 股东发布集体诉讼通知 [1] - 诉讼针对在2025年5月19日至2025年6月3日期间购买公司公开交易证券的投资者 [3] - 诉讼还涵盖通过公司2025年5月21日二次公开发行购买证券的投资者 [3] 指控内容 - 被告被指控在集体诉讼期间发布 materially false and/or misleading statements [4] - 公司声称已重启加利福尼亚海岸的石油生产但实际上并未实现 [4] - 被告关于公司业务、运营和前景的陈述存在 materially false and misleading 且缺乏合理依据 [4] - 真相披露后投资者遭受损失 [4] 时间安排 - 股东参与集体诉讼的截止日期为2025年9月26日 [5] - 寻求成为首席原告的截止日期同样为2025年9月26日 [5] 参与方式 - 股东可通过特定网址进行登记注册 [2][5] - 登记后股东将加入投资组合监控软件以获取案件状态更新 [5] - 参与本案无需任何成本或义务 [5]

法律调查事件 - Pomerantz LLP正在调查Summit Therapeutics Inc 是否涉及证券欺诈或其他非法商业行为 [1] 临床实验结果 - 2025年5月30日公司公布ivonescimab联合化疗的三期临床研究HARMONi顶线结果 显示治疗组疾病进展或死亡风险降低48% 但未达到总生存期的主要终点统计学显著性 [3] - 2025年9月7日公司补充发布试验数据 显示ivonescimab在北美和欧洲患者中的疗效表现弱于其他地区患者 [4] 股价波动 - 2025年5月30日临床数据公布后 公司股价单日下跌7.99美元 跌幅达30.5% 收盘报18.22美元 [4] - 2025年9月8日地区疗效差异数据披露后 公司股价单日下跌6.54美元 跌幅达25.15% 收盘报19.45美元 [4]